RxDoctor Payments DataLook up a doctor →

Natalie Tellez, APRN

Psychiatric/Mental Health · Houston, TXNPI 1730433947

Payments from drug & device makers

$602,177in general payments, 2019–2025

Across 1,329 payments — averaging $453.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$435K
  • Vanda Pharmaceuticals Inc.$115K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$41K
  • Otsuka America Pharmaceutical, Inc.$9K
  • Neurocrine Biosciences, Inc.$413
  • Corium, LLC$377
  • plus $2K from 16 others

What the payments were for

  • Consulting fees$5,3251%
  • Speaking & faculty fees$485,78581%
  • Travel & lodging$91,69515%
  • Food & beverage$19,3343%
  • Education$380%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$602,177 in reported general payments places this provider in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.

See all psychiatric/mental health providers in Texas

Medicare billing

Part B allowed, 2024
$11,567
Medicare patients
26
Services billed
155

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate11$93,189
Duloxetine Hcl65$2,513
Bupropion XlBupropion Hcl48$1,448
Quetiapine Fumarate69$1,150
Ziprasidone Hcl18$797
Trazodone Hcl61$767
Clonazepam73$718
Escitalopram Oxalate63$702
Buspirone Hcl46$624
Mirtazapine20$498
Prazosin Hcl13$449
Divalproex Sodium ErDivalproex Sodium18$444
Aripiprazole19$384
Venlafaxine Hcl ErVenlafaxine Hcl15$379
Lamotrigine31$329

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$413$93,18911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.

Other psychiatric/mental health in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →